Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-08-15, Stock:LLY, The news for the past five days is as follows:
2019-08-08: NEWS1: Top Stock Reports: Disney, Eli Lilly, ADP & More.NEWS2: Top Stock Reports: Disney, Eli Lilly, ADP & More.NEWS3: Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss.NEWS4: Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss.NEWS5: Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid.NEWS6: Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid.NEWS7: Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down.NEWS8: Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down.NEWS9: Top Stock Reports: Disney, Eli Lilly, ADP & More.NEWS10: Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss.NEWS11: Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid.NEWS12: Lilly Announces Positive Results for Emgality™ (galcanezumab) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments.NEWS13: Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down.NEWS14: UPDATE 1-Study shows Apple devices in combo with apps could identify dementia.NEWS15: Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia.
2019-08-09: NEWS1: Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss.NEWS2: Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss.NEWS3: Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2.NEWS4: Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2.NEWS5: U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit.NEWS6: Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients.NEWS7: Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients.NEWS8: Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates.NEWS9: Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates.NEWS10: Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss.NEWS11: Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2.NEWS12: Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients.NEWS13: Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates.
2019-08-12: NEWS1: Noteworthy ETF Outflows: IVW, KO, LLY, FIS.NEWS2: Noteworthy ETF Outflows: IVW, KO, LLY, FIS.
2019-08-13: NEWS1: Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study.NEWS2: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 14, 2019.NEWS3: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 14, 2019.NEWS4: 8 Stocks That Have Paid a Dividend for 125 (or More) Consecutive Years.NEWS5: 8 Stocks That Have Paid a Dividend for 125 (or More) Consecutive Years.NEWS6: Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis.NEWS7: 8 Stocks That Have Paid a Dividend for 125 (or More) Consecutive Years.NEWS8: How one Boston startup rode the diabetes investment wave to raise $126M.
2019-08-14: NEWS1: Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?.NEWS2: Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?.NEWS3: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS4: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS5: Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?.NEWS6: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS7: Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health.

Answer: Decrease